Long-Term Outcome and MGMT as a Predictive Marker in 24 Patients With Atypical Pituitary Adenomas and Pituitary Carcinomas Given Treatment With Temozolomide
Daniel Bengtsson, Henrik Daa Schrøder, Marianne Andersen, Dominique Maiter, Katarina Berinder, Ulla Feldt Rasmussen, Åse Krogh Rasmussen, Gudmundur Johannsson, Charlotte Hoybye, Aart Jan van der Lely, Maria Petersson, Oskar Ragnarsson, Pia Burman
Dive into the research topics of 'Long-Term Outcome and MGMT as a Predictive Marker in 24 Patients With Atypical Pituitary Adenomas and Pituitary Carcinomas Given Treatment With Temozolomide'. Together they form a unique fingerprint.